Drug intelligence / Profile preview

UKK-0018

Development stage: Phase 2
Lead developer: Ukko
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

UKK-0018 is an mRNA-based immunotherapy developed by Ukko, a biotech company specializing in mRNA-based immunotherapies for allergies. It is Ukko's lead program, specifically designed for the treatment of peanut allergy. The drug is advancing into a Phase 1/2a clinical trial, with the goal of providing a safer alternative to traditional allergy desensitization methods.

Targets

Peanut-specific IgE (Peanut-specific immunoglobulin E)Peanut allergen-specific T cell receptor

Beyond the preview

Go deeper on UKK-0018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UKK-0018.

Explore the full profile